PMID- 25903069
OWN - NLM
STAT- MEDLINE
DCOM- 20160623
LR  - 20181113
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
VI  - 60
IP  - 11
DP  - 2015 Nov
TI  - Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid 
      arthritis.
PG  - 691-6
LID - 10.1038/jhg.2015.36 [doi]
AB  - Human leukocyte antigen (HLA) polymorphisms are the most important genetic risk 
      factors for rheumatoid arthritis (RA), a chronic systemic inflammatory disease of 
      unknown etiology. Certain HLA-DRB1 alleles, known as shared epitope (SE) alleles 
      because they have the same amino-acid sequence at positions 70-74, are associated 
      with susceptibility to RA. A gene dosage effect is present for RA-predisposing SE 
      alleles, and protective alleles show epistasis. An important role of amino-acid 
      polymorphisms at positions 11 and 13 of the HLA-DRbeta chain was also reported 
      recently. Rheumatoid factor and anticitrullinated peptide antibodies are present 
      in many RA patients. Similar to extra-articular manifestations, the presence of 
      these autoantibodies is also associated with certain DRB1 alleles. Different 
      frequencies of RA risk alleles in different ethnicities explain the varying 
      prevalence of RA in different populations and suggest genetic heterogeneity of RA 
      with regard to phenotype and population subsets. Some drug-induced 
      hypersensitivity reactions due to disease-modifying antirheumatic drugs are also 
      associated with HLA alleles. Understanding the role of HLA as the most important 
      genetic factor relevant to RA susceptibility may help in determining its 
      pathogenesis and pave the way to personalized medicine.
FAU - Furukawa, Hiroshi
AU  - Furukawa H
AUID- ORCID: 0000-0002-4022-0767
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sagamihara, Japan.
FAU - Oka, Shomi
AU  - Oka S
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sagamihara, Japan.
FAU - Shimada, Kota
AU  - Shimada K
AD  - Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, 
      Sagamihara, Japan.
AD  - Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, 
      Japan.
FAU - Hashimoto, Atsushi
AU  - Hashimoto A
AD  - Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, 
      Sagamihara, Japan.
FAU - Tohma, Shigeto
AU  - Tohma S
AD  - Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, 
      National Hospital Organization, Sagamihara, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150423
PL  - England
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Antirheumatic Agents/adverse effects
MH  - Arthritis, Rheumatoid/drug therapy/*genetics/*immunology
MH  - Drug Hypersensitivity/genetics/immunology
MH  - Genetic Predisposition to Disease
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Polymorphism, Genetic
MH  - Precision Medicine
EDAT- 2015/04/24 06:00
MHDA- 2016/06/24 06:00
CRDT- 2015/04/24 06:00
PHST- 2015/02/22 00:00 [received]
PHST- 2015/03/12 00:00 [revised]
PHST- 2015/03/12 00:00 [accepted]
PHST- 2015/04/24 06:00 [entrez]
PHST- 2015/04/24 06:00 [pubmed]
PHST- 2016/06/24 06:00 [medline]
AID - jhg201536 [pii]
AID - 10.1038/jhg.2015.36 [doi]
PST - ppublish
SO  - J Hum Genet. 2015 Nov;60(11):691-6. doi: 10.1038/jhg.2015.36. Epub 2015 Apr 23.